Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07621471
EARLY_PHASE1

IL-15 Enhanced NK Cell Therapy for Solid Tumors

Sponsor: Genovn Therapeutics (Suzhou) Co., Ltd.

View on ClinicalTrials.gov

Summary

A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.

Official title: A Single-Arm Clinical Study of IL-15 Enhanced Engineered NK Cells for Refractory Relapsed/Metastatic Solid Tumors

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2026-07-01

Completion Date

2028-12-31

Last Updated

2026-06-02

Healthy Volunteers

No

Interventions

DRUG

IL-15 enhanced engineered NK cells

Genetically engineered NK cells expressing IL-15. Administered intravenously. See protocol for dose details.

BIOLOGICAL

IL-15 Enhanced Engineered NK Cells

Genetically engineered NK cells expressing IL-15

Locations (1)

Xinqiao Hospital

Chongqing, China